Merck to Buy Tilos Therapeutics for Up to $773 Million
June 10 2019 - 07:37AM
Dow Jones News
By Colin Kellaher
Merck & Co. (MRK) on Monday said it agreed to buy Tilos
Therapeutics, a privately held biopharmaceutical company developing
therapeutics for the treatment of cancer, fibrosis and autoimmune
diseases, for up to $773 million.
The Kenilworth, N.J., drug maker said the figure includes an
upfront payment and contingent milestone payments.
Merck said Tilos is developing therapeutics targeting
TGF<BETA>, a potent cytokine believed to play an important
role in the development of cancer and fibrotic diseases.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 10, 2019 07:22 ET (11:22 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2023 to Mar 2024